Samarth Kulkarni - 29 Jan 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
29 Jan 2024
Net transactions value
-$2,069,573
Form type
4
Filing time
31 Jan 2024, 17:45:05 UTC
Previous filing
18 Jan 2024
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $956,000 +50,000 +27% $19.12 237,377 29 Jan 2024 Direct
transaction CRSP Common Shares Sale $2,982,803 -49,300 -21% $60.50 188,077 29 Jan 2024 Direct F1, F2
transaction CRSP Common Shares Sale $42,770 -700 -0.37% $61.10 187,377 29 Jan 2024 Direct F1, F3
holding CRSP Common Shares 200,000 29 Jan 2024 The Kulkarni 2023 GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise -50,000 -33% 100,000 29 Jan 2024 Common Shares 50,000 $19.12 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.04 to $61.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.04 to $61.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 This performance-based stock option was granted on December 1, 2017 with respect to 150,000 Common Shares and was subject to both time- and performance-based vesting. Performance-based stock options vested as to 112,500 options on December 1, 2020 and 37,500 options on December 1, 2021, based on the Company's performance over the applicable performance period, and subject to the terms and conditions of the agreement evidencing the award and the Company's 2016 Stock Option and Incentive Plan.
F5 Not applicable.